从资金流向上来看，当日专业服务板块主力资金净流出2.92亿元，游资资金净流入1490.58万元，散户资 金净流入2.77亿元。专业服务板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 证券之星消息，12月17日专业服务板块较上一交易日下跌0.5%，谱尼测试领跌。当日上证指数报收于 3870.28，上涨1.19%。深证成指报收于13224.51，上涨2.4%。专业服务板块个股涨跌见下表： ...

中国经济网北京12月17日讯 谱尼测试(300887.SZ)日前披露2025年三季度报告。前三季度，谱尼测试实现营业总 收入9.32亿元，同比下降17.01%；归属于上市公司股东的净利润-1.99亿元，上年同期为-2.34亿元；归属于上市公司 股东的扣除非经常性损益的净利润-2.02亿元，上年同期为-2.46亿元；经营活动产生的现金流量净额为-2730.29万元， 上年同期为-1.16亿元。 | | 本报告期 | 本报告期比上年同期 增减 | 年初至报告期末 | 年初至报告期末比上 年同期增减 | | --- | --- | --- | --- | --- | | 营业收入(元) | 367, 541, 572. 52 | -7.03% | 932, 345, 577. 74 | -17.01% | | 归属于上市公司股东 的净利润(元) | -19, 206, 031. 90 | 69. 40% | -198,864,522.01 | 15. 07% | | 归属于上市公司股东 的扣除非经常性损益 | -21, 334, 539. 10 | 68. 36% | -202, 071, 342. 22 | 17 ...

（文章来源：证券日报） 证券日报网讯 12月16日，谱尼测试在互动平台回答投资者提问时表示，公司多年来一直从事多类装备 的环境与可靠性产品试验、电磁兼容试验和软件测评服务，经过公司多年的发展，已形成从元器件级- 部件级-分系统级-系统级较为齐全的气候、机械、综合环境等环境可靠性试验服务能力；同时，公司还 具备可靠性试验方案设计与制定、产品故障分析与诊断等一站式综合服务能力，整体试验的资质和服务 的试验项目种类齐全、试验设备先进，客户群体涵盖了航空、航天、船舶、兵器、汽车、电子等特殊行 业。航天器及配套设备的部分环境与可靠性试验标准已通过资质认可，为公司服务商业航天提供了坚实 的基础，公司正大力推进客户的拓展，推进市场，提升产能。 ...

Market Overview - The professional services sector experienced a decline of 1.09% on the previous trading day, with Guoyi Tender leading the drop [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Stock Performance - Notable gainers in the professional services sector included: - Xince Standard (300938) with a closing price of 33.10, up 3.60% on a trading volume of 166,000 shares and a turnover of 54.5 million yuan [1] - Beikang Testing (920160) closed at 27.42, up 3.47% with a trading volume of 138,900 shares and a turnover of 386 million yuan [1] - Major decliners included: - Guoyi Tender (920039) which closed at 12.56, down 4.56% with a trading volume of 26,200 shares and a turnover of 33.38 million yuan [2] - Lingdian Youshu (301169) closed at 42.50, down 4.39% with a trading volume of 17,000 shares and a turnover of 73.66 million yuan [2] Capital Flow - The professional services sector saw a net outflow of 251 million yuan from institutional investors, while retail investors experienced a net inflow of 131 million yuan [2] - The capital flow for specific stocks showed: - Xince Standard (300938) had a net outflow of 24.63 million yuan from institutional investors [3] - Puni Testing (300887) recorded a net inflow of 17.98 million yuan from retail investors [3]

Core Insights - The medical testing industry is facing significant challenges due to increased accounts receivable and declining profits, particularly following the COVID-19 pandemic [1][4][5] Group 1: Accounts Receivable and Financial Performance - Four companies have accounts receivable exceeding 2 billion yuan, with Capbio (凯普生物) involved in lawsuits to recover 357 million yuan in overdue payments [1] - In the first three quarters of this year, at least seven medical testing companies reported net losses attributable to shareholders, with six of them expected to continue this trend into 2024 [1] - Specific losses reported include: Puni Testing (谱尼测试) at 199 million yuan, RunDa Medical (润达医疗) at 163 million yuan, and Capbio at 128 million yuan [1] Group 2: Impact of Price Reductions and Impairment Provisions - Price reductions in the testing sector have led to widespread profit shrinkage among medical testing companies, with some firms making impairment provisions for accounts receivable [4] - Companies like KingMed Diagnostics (金域医学) have made significant impairment provisions, totaling 345 million yuan, primarily for accounts receivable, which reduced their consolidated profit by the same amount [4] - Lanwei Medical (兰卫医学) reported a total impairment provision of 16.73 million yuan, with 13.50 million yuan specifically for accounts receivable [5] Group 3: Recovery Trends and Future Outlook - The Ministry of Finance has indicated a commitment to debt reduction policies, which may accelerate the collection of accounts receivable from public hospitals [5] - Companies are implementing strategies to manage accounts receivable more effectively, with Puni Testing focusing on tailored collection strategies for major clients [6] - DiAn Diagnostics (迪安诊断) anticipates improved collection trends in the second half of the year, with expectations that all COVID-related accounts receivable will be fully provisioned by year-end [5][6]

Group 1: Financial Performance - The company's Q3 2025 revenue increased by 17.39% compared to Q2 2025 [3] - Cumulative net profit attributable to shareholders improved by 15.07% year-on-year for the first three quarters of 2025 [3] - Operating cash flow improved significantly by 76.50% year-on-year for the first three quarters of 2025 [3] Group 2: Strategic Focus - The company is focused on "cost reduction and efficiency enhancement" and "profit recovery" as core objectives [2] - The company aims to strengthen cash flow management and promote stable overall operations [3] - New business segments, particularly in biomedicine and medical devices, are showing strong growth potential [3] Group 3: Recognition and Achievements - The company received an AA rating in the 2025 Wind ESG assessment, ranking among only 4 out of 90 peers [2] - Several subsidiaries were awarded "specialized, refined, distinctive, and innovative" and "quality star" titles, showcasing the company's strength in technology innovation and quality management [3] Group 4: Management and Operational Strategies - The company has implemented strict cost control measures and optimized business models to uncover cost potential [3] - A comprehensive accounts receivable management system has been established to enhance cash flow structure [3] - The company is actively considering mergers and acquisitions, focusing on sectors like medical devices, semiconductor chips, and new energy [4] Group 5: Client Management - The company is adjusting its client structure, maintaining close cooperation with key government clients while reducing exposure to clients with long payment cycles [6] - Corporate clients are increasingly contributing to revenue, with a continuous increase in their revenue share [6]

Core Viewpoint - The company, Puni Testing, is a leading comprehensive testing and certification service provider in China, facing challenges in revenue and profitability but showing signs of improvement in recent quarters [1][6]. Group 1: Business Performance - In Q3 2025, Puni Testing reported revenue of 932 million yuan, ranking 7th among 21 companies in the industry, with the industry leader, Huace Testing, generating 4.702 billion yuan [2]. - The company's net profit for the same period was -198 million yuan, placing it 21st in the industry, while the top performer, Huace Testing, achieved a net profit of 810 million yuan [2]. - The main business segments include Life Sciences and Environmental Health (367 million yuan, 68.89%), Automotive and Other Consumer Goods (106 million yuan, 19.99%), and Safety Assurance (58.26 million yuan, 10.94%) [2]. Group 2: Financial Ratios - As of Q3 2025, Puni Testing's debt-to-asset ratio was 16.10%, lower than the previous year's 18.99% and below the industry average of 26.67%, indicating strong solvency [3]. - The gross profit margin for the same period was 29.61%, an increase from 28.24% year-on-year, but still below the industry average of 43.39%, suggesting room for improvement in profitability [3]. Group 3: Management and Shareholder Information - The chairman, Song Wei, received a salary of 872,000 yuan in 2024, a decrease of 34,800 yuan from 2023 [4]. - The number of A-share shareholders decreased by 15.81% to 21,400 as of September 30, 2025, while the average number of shares held per shareholder increased by 18.79% [5]. Group 4: Future Outlook - Longjiang Securities noted that while Puni Testing faced revenue decline and net losses in the first three quarters of 2025, the revenue decline has narrowed significantly in Q3, and the company is expected to focus on biomedicine and cosmetics to enhance laboratory capacity utilization [6]. - Revenue projections for 2025 to 2027 are 1.365 billion yuan, 1.586 billion yuan, and 1.819 billion yuan, with net profits expected to improve from -134 million yuan in 2025 to 145 million yuan in 2027 [6].

Core Viewpoint - The stock price of Puni Testing has shown a decline recently, with a year-to-date increase of only 4.32% and a significant drop over the past 60 days of 9.64% [2]. Financial Performance - For the period from January to September 2025, Puni Testing reported a revenue of 932 million yuan, representing a year-on-year decrease of 17.01%. The net profit attributable to shareholders was -199 million yuan, which is a 15.07% increase compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 336 million yuan, with 234 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Puni Testing was 21,400, a decrease of 15.81% from the previous period. The average circulating shares per person increased by 18.79% to 16,937 shares [2]. - The top ten circulating shareholders include new entrant Guangfa Quantitative Multi-Factor Mixed A, holding 2.6622 million shares, and Hong Kong Central Clearing Limited, which increased its holdings by 293,000 shares to 2.3108 million shares [3]. Market Activity - On October 29, Puni Testing's stock price fell by 2.09%, trading at 7.97 yuan per share with a total market capitalization of 4.35 billion yuan. The net inflow of main funds was 553,600 yuan, with large single purchases accounting for 6.63% of the total [1].

Investment Rating - The investment rating for the company is "Buy" and is maintained [9]. Core Views - The company reported a revenue of 932 million yuan for the first three quarters, a year-on-year decline of 17.0%, with a net profit attributable to the parent company of -199 million yuan. In Q3 2025, revenue was 368 million yuan, down 7.0% year-on-year, but the net profit showed a significant reduction in losses [2][6]. - Looking ahead to Q4 2025 and 2026, the company is expected to see continued profit improvement due to reduced bad debt impairment pressure and a recovery in demand from the biopharmaceutical, military, and new energy vehicle sectors [2]. Summary by Sections Revenue Performance - In Q3 2025, the revenue decline narrowed significantly compared to earlier quarters, with a drop of 7.0% compared to Q1's -24.7% and Q2's -20.5%. The company faced revenue pressure due to industry-specific events affecting military and biopharmaceutical testing, as well as adjustments in customer structure leading to a decline in government orders [14]. - For H1 2025, revenue by business segment showed a decline in life sciences and environmental protection by 27.05%, while automotive and other consumer goods fell by 17.85%. However, safety assurance revenue increased by 10.02% [14]. Profitability Analysis - The net profit for 2024 and H1 2025 was significantly negative, but Q3 2025 showed a notable reduction in losses. The losses were attributed to rigid costs during customer structure adjustments, increased competition in the biopharmaceutical sector, and initial high investments in newly expanded special equipment testing [14]. - The company expects to turn profitable as revenue recovers and the risks associated with asset and credit impairments decrease [14]. Cash Flow and Financial Projections - Despite significant net losses in 2024, the operating cash flow was positive at 36 million yuan. For Q1-Q3 2025, the cash flow improved to -27 million yuan, a notable improvement from -116 million yuan in the previous year [14]. - Revenue projections for 2025-2027 are 1.365 billion yuan, 1.586 billion yuan, and 1.819 billion yuan, with expected year-on-year growth rates of -11.4%, 16.1%, and 14.7% respectively. The net profit is projected to gradually recover, reaching 145 million yuan by 2027 [19].

Core Insights - The company reported a total operating revenue of 932 million yuan, a decrease of 191 million yuan compared to the same period last year, representing a year-on-year decline of 17.01% [2] - The net profit attributable to shareholders was -199 million yuan, indicating a loss [2] - The net cash inflow from operating activities was -27.3 million yuan [2] Financial Metrics - The latest debt-to-asset ratio stands at 16.10% [4] - The latest gross profit margin is 29.61% [4] - The return on equity (ROE) is -6.93% [4] - The diluted earnings per share (EPS) is -0.36 yuan [4] - The total asset turnover ratio is 0.26 times, a decrease of 0.01 times compared to the same period last year, reflecting a year-on-year decline of 5.39% [4] - The inventory turnover ratio is 20.06 times, a decrease of 12.46 times compared to the same period last year, representing a year-on-year decline of 38.32% [4] Shareholder Structure - The number of shareholders is 21,400, with the top ten shareholders holding 344 million shares, accounting for 63.06% of the total share capital [4] - The largest shareholder is Song Wei, holding 44.33% of the shares [4] - Other notable shareholders include Li Yanggu (9.59%) and Beijing Puri Hengxiang Technology Development Co., Ltd. (3.58%) [4]